Scientists target Cancer's weak spot: redox imbalance
NCT ID NCT06600568
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks for new ways to kill T-cell leukemia and lymphoma cells by disrupting their internal balance of reactive oxygen species. Researchers will test drug combinations in lab-grown cells and in samples from 120 patients with resistant disease. The goal is to find treatments that can selectively eliminate cancer cells while sparing healthy ones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Drug combinations targeting redox homeostasis (e.g., venetoclax with G6PD inhibitors)
What this could lead to
If successful, this could point toward new treatment options for patients with resistant T-cell cancers.
What could go wrong
This is an early translational study using lab and patient samples, not a treatment trial. Results may not lead to effective therapies for people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LEUKEMIA/LYMPHOMA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori Fondazione G.Pascale
RECRUITINGNaples, 80100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Istituto Oncologico Veneto
RECRUITINGPadova, 35128, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••